Cyclerion receives Nasdaq deficiency notice for bid price below $1; 180-day cure period to Nov 28, 2022

Cyclerion Therapeutics, Inc.

Received Nasdaq deficiency letter on June 1, 2022, for failing minimum $1 bid price for 30 consecutive business days.
Has until November 28, 2022, to regain compliance with bid price closing at $1 for 10 consecutive days.
May transfer to Nasdaq Capital Market or effect a reverse stock split if needed to cure the deficiency.
No assurance of regaining compliance; failure could lead to delisting and appeal process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.